Delaware
|
94-3023969
|
(State or Other Jurisdiction of Incorporation)
|
(I.R.S. Employer Identification No.)
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Exhibit No.
|
Description
|
|
99.1
|
Presentation
|
|
99.2
|
Press Release, dated May 24, 2011
|
PDL BIOPHARMA, INC.
|
||
(Company)
|
||
By:
|
/s/ Christine R. Larson
|
|
Christine R. Larson
|
||
Vice President and Chief Financial Officer
|
Company:
|
PDL BioPharma, Inc.
|
Ticker:
|
PDLI (NASDAQ)
|
Location:
|
Incline Village, Nevada
|
Employees:
|
Less than 10
|
2010 Revenues:
|
$345 million
|
2011- Q1 Revenue:
|
$83 million
|
2011 Regular Dividends:
|
$0.15 /share paid on March 15, June 15,
September 15 & December 15 |
Q1-2011 Cash Position1:
|
$193 million
|
Shares O/S2:
|
~ 140 million
|
Average Daily Volume:
|
~ 3 million shares
|
Genentech Product Made or Sold in U.S.
|
|
Net Sales up to $1.5 Billion
|
3.0%
|
Net Sales Between $1.5 Billion and $2.5 Billion
|
2.5%
|
Net Sales Between $2.5 Billion and $4.0 Billion
|
2.0%
|
Net Sales Over $4.0 Billion
|
1.0%
|
Genentech Product Made and Sold Ex-U.S.
|
|
All Sales
|
3.0%
|
Licensee
|
Product
|
Status
|
Indications
|
Roche (Genentech)
|
Avastin
|
Approved
sBLA
Phase 3
|
Colorectal Cancer
NSCLC
Metastatic Renal Cell
Glioblastoma
Metastatic Breast HER2- 1st Line
Metastatic Breast HER2- 2nd Line
Ovarian Cancer
Gastric
|
|
|||
|
|||
|
|||
Elan
|
|||
Licensee
|
Product
|
Status
|
Indications
|
Roche (Genentech)
|
Avastin
|
Approved
sBLA
Phase 3
|
Colorectal Cancer
NSCLC
Metastatic Renal Cell
Glioblastoma
Metastatic Breast HER2- 1st Line
Metastatic Breast HER2- 2nd Line
Ovarian Cancer
Gastric
|
|
|||
|
|||
|
|||
Elan
|
|||
Phase 2 ISP
|
Retinopathy of Prematurity
|
||
|
Herceptin
|
Approved
|
Breast HER2+ Cancer
HER2+ Stomach and Gastro-Esophageal cancers
|
|
Lucentis
|
Approved
Approved
Phase 3
|
AMD
RVO
DME
|
|
Xolair
|
Approved
sBLA
|
Moderate-Severe Asthma
Pediatric Asthma
|
Elan
|
Tysabri
|
Approved
|
Multiple Sclerosis
|
Roche (Chugai)
|
Actemra
|
Approved
|
Rheumatoid Arthritis
|
|
|||
|
Lucentis
|
Approved
Approved
Phase 3 (US)
|
AMD
RVO
DME
|
|
Xolair
|
Approved
sBLA
|
Moderate-Severe Asthma
Pediatric Asthma
|
Elan
|
Tysabri
|
Approved
|
Multiple Sclerosis
|
Roche (Chugai)
|
Actemra
|
Approved
|
Rheumatoid Arthritis
|
|
|||
|
Lucentis
|
Approved
Approved
Phase 3
|
AMD
RVO
DME
|
|
Xolair
|
Approved
sBLA
|
Moderate-Severe Asthma
Pediatric Asthma
|
Elan
|
Tysabri
|
Approved
|
Multiple Sclerosis
|
Roche (Chugai)
|
Actemra
|
Approved
|
Rheumatoid Arthritis
|
Licensee
|
Product
|
Status
|
Indications
|
|
HER2+ Stomach and Gastro-Esophageal cancers
|
||
|
Lucentis
|
Approved
Approved
Phase 3
|
AMD
RVO
DME
|
|
Xolair
|
Approved
sBLA
|
Moderate-Severe Asthma
Pediatric Asthma
|
Elan
|
Tysabri
|
Approved
|
Multiple Sclerosis
|
Roche (Chugai)
|
Actemra
|
Approved
|
Rheumatoid Arthritis
|
|
|||
|
Lucentis
|
Approved
Approved
Phase 3
|
AMD
RVO
DME
|
|
Xolair
|
Approved
sBLA
|
Moderate-Severe Asthma
Pediatric Asthma
|
Elan
|
Tysabri
|
Approved
|
Multiple Sclerosis
|
Roche (Chugai)
|
Actemra
|
Approved
|
Rheumatoid Arthritis
|
Licensee
|
Product
|
Status
|
Indications
|
|
|||
|
|||
|
Xolair
|
Approved
sBLA
|
Moderate-Severe Asthma
Pediatric Asthma
|
Elan
|
Tysabri
|
Approved
|
Multiple Sclerosis
|
Roche (Chugai)
|
Actemra
|
Approved
|
Rheumatoid Arthritis
|
Licensee
|
Product
|
Status
|
Indications
|
Roche (Genentech)
|
Avastin
|
Approved
|
Colorectal Cancer
NSCLC
|
|
|||
|
Phase 3
|
DME
|
|
|
Xolair
|
Approved
sBLA
|
Moderate-Severe Asthma
Pediatric Asthma
|
Elan
|
Tysabri
|
Approved
|
Multiple Sclerosis
|
Roche (Chugai)
|
Actemra
|
Approved
|
Rheumatoid Arthritis
|
Licensee
|
Product
|
Status
|
Indications
|
Roche (Genentech)
|
T-DM1
|
Phase 2 & 3
|
Breast HER2+ Cancer
|
|
Ocrelizumab
|
Phase 2b
|
Relapsing Remitting Multiple Sclerosis
|
|
Pertuzumab
|
Phase 3
|
Metastatic HER2+ Breast Cancer
|
Roche
|
Afutuzumab
|
Phase 3
|
Chronic Lymphocytic Leukemia
|
Elan/J&J/Pfizer
|
Bapineuzumab
|
Phase 3
|
Alzheimer’s Disease
|
Lilly
|
|||
Eisai
|
Licensee
|
Product
|
Status
|
Indications
|
Roche (Genentech)
|
T-DM1
|
Phase 2 & 3
|
Breast HER2+ Cancer
|
|
Ocrelizumab
|
Phase 2b
|
Relapsing Remitting Multiple Sclerosis
|
|
Pertuzumab
|
Phase 3
|
Metastatic HER2+ Breast Cancer
|
Roche
|
Afutuzumab
|
Phase 3
|
Chronic Lymphocytic Leukemia
|
Elan/J&J/Pfizer
|
Bapineuzumab
|
Phase 3
|
Alzheimer’s Disease
|
Lilly
|
Solanezumab
|
Phase 3
|
Alzheimer’s Disease
|
Cris Larson
|
Jennifer Williams
|
PDL BioPharma, Inc.
|
Cook Williams Communications, Inc.
|
775-832-8505
|
360-668-3701
|
Cris.Larson@pdl.com
|
jennifer@cwcomm.org
|
|
·
|
The expected rate of growth in royalty-bearing product sales by PDL’s existing licensees;
|
|
·
|
The relative mix of royalty-bearing Genentech products manufactured and sold outside the U.S. versus manufactured or sold in the U.S.;
|
|
·
|
The ability of our licensees to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, will be commercially successful;
|
|
·
|
Changes in any of the other assumptions on which PDL’s projected royalty revenues are based;
|
|
·
|
The outcome of pending litigation or disputes;
|
|
·
|
The change in foreign currency exchange rates; and
|
|
·
|
The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.
|
9@2>:KRV8#$F1B3ZBG9V"Z%COE8`2K@^HJVI#KE&R*S3
M"J]R:%)B.4.*$WU"Q=DC)J!H]IR<"KNS*:T0/85#'*4.#R
M*M`Y&:M68MB'85^ZQ%`:0=@U34A4&BP$8F'<$4\.K="*"F>],,0]/RHU`EHJ
M#:R_=U',^X713-EI@7)T;3/_``%3_"H7M]-4
M<:-I?_@(M79!@&J